Do analysts recommend BMRA or PLRZ?

Biomerica currently has a consensus price target of $9.00, indicating a potential upside of 334.78%. Given Biomerica's higher possible upside, equities research analysts plainly believe Biomerica is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BMRA or PLRZ?

Polyrizon has lower revenue, but higher earnings than Biomerica. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $4.33M 1.48 -$4.97M -$0.89 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is BMRA or PLRZ more profitable?

Polyrizon has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Polyrizon's return on equity of 0.00% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% Polyrizon N/A N/A N/A

Does the media prefer BMRA or PLRZ?

In the previous week, Polyrizon had 5 more articles in the media than Biomerica. MarketBeat recorded 6 mentions for Polyrizon and 1 mentions for Biomerica. Biomerica's average media sentiment score of 0.67 beat Polyrizon's score of 0.66 indicating that Biomerica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NEUP or BMRA?

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Biomerica's average media sentiment score of 0.67 beat Neuphoria Therapeutics' score of 0.00 indicating that Biomerica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomerica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KYNB or BMRA?

Biomerica has a consensus target price of $9.00, indicating a potential upside of 334.78%. Given Biomerica's higher probable upside, analysts clearly believe Biomerica is more favorable than Kyntra Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, KYNB or BMRA?

Kyntra Bio has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $7.44M 3.61 $183.45M $40.46 0.16 Biomerica $4.33M 1.48 -$4.97M -$0.89 N/A

Is KYNB or BMRA more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Biomerica's net margin of -96.49%. Kyntra Bio's return on equity of 0.00% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% Biomerica -96.49% -98.14% -70.42%

Does the media refer more to KYNB or BMRA?

In the previous week, Kyntra Bio and Kyntra Bio both had 1 articles in the media. Biomerica's average media sentiment score of 0.67 beat Kyntra Bio's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomerica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biomerica (BMRA) Competitors

$2.07 -0.05 (-2.36%)

Closing price 03:58 PM Eastern

Extended Trading

$2.06 -0.01 (-0.48%)

As of 04:10 PM Eastern

Compare

BMRA vs. PLRZ, NEUP, DYAI, KYNB, and BRNS

Should you buy Biomerica stock or one of its competitors? MarketBeat compares Biomerica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomerica include Polyrizon (PLRZ), Neuphoria Therapeutics (NEUP), Dyadic International (DYAI), Kyntra Bio (KYNB), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry.

How does Biomerica compare to Polyrizon?

Biomerica (NASDAQ:BMRA) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

In the previous week, Polyrizon had 5 more articles in the media than Biomerica. MarketBeat recorded 6 mentions for Polyrizon and 1 mentions for Biomerica. Biomerica's average media sentiment score of 0.67 beat Polyrizon's score of 0.66 indicating that Biomerica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomerica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Polyrizon has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Polyrizon's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Polyrizon	N/A	N/A	N/A

Biomerica has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.9, indicating that its share price is 290% less volatile than the broader market.

22.3% of Biomerica shares are held by institutional investors. 18.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Polyrizon has lower revenue, but higher earnings than Biomerica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.48	-$4.97M	-$0.89	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Biomerica currently has a consensus price target of $9.00, indicating a potential upside of 334.78%. Given Biomerica's higher possible upside, equities research analysts plainly believe Biomerica is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biomerica beats Polyrizon on 6 of the 11 factors compared between the two stocks.

How does Biomerica compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Neuphoria Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 349.68%. Biomerica has a consensus price target of $9.00, indicating a potential upside of 334.78%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 1 articles in the media. Biomerica's average media sentiment score of 0.67 beat Neuphoria Therapeutics' score of 0.00 indicating that Biomerica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomerica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuphoria Therapeutics has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.61	-$370K	-$11.06	N/A
Biomerica	$4.33M	1.48	-$4.97M	-$0.89	N/A

Neuphoria Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Neuphoria Therapeutics' return on equity of -76.93% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Biomerica	-96.49%	-98.14%	-70.42%

Neuphoria Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Neuphoria Therapeutics beats Biomerica on 11 of the 15 factors compared between the two stocks.

How does Biomerica compare to Dyadic International?

Biomerica (NASDAQ:BMRA) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Biomerica currently has a consensus target price of $9.00, indicating a potential upside of 334.78%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 329.18%. Given Biomerica's higher probable upside, research analysts clearly believe Biomerica is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Biomerica had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Biomerica and 0 mentions for Dyadic International. Biomerica's average media sentiment score of 0.67 beat Dyadic International's score of 0.00 indicating that Biomerica is being referred to more favorably in the media.

Company	Overall Sentiment
Biomerica	Positive
Dyadic International	Neutral

Biomerica has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biomerica has a net margin of -96.49% compared to Dyadic International's net margin of -192.40%. Biomerica's return on equity of -98.14% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Biomerica has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.48	-$4.97M	-$0.89	N/A
Dyadic International	$3.09M	8.24	-$7.36M	-$0.23	N/A

Summary

Biomerica beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Biomerica compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Biomerica (NASDAQ:BMRA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Kyntra Bio has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Biomerica has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, Kyntra Bio and Kyntra Bio both had 1 articles in the media. Biomerica's average media sentiment score of 0.67 beat Kyntra Bio's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomerica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$7.44M	3.61	$183.45M	$40.46	0.16
Biomerica	$4.33M	1.48	-$4.97M	-$0.89	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Biomerica's net margin of -96.49%. Kyntra Bio's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Biomerica	-96.49%	-98.14%	-70.42%

Biomerica has a consensus target price of $9.00, indicating a potential upside of 334.78%. Given Biomerica's higher probable upside, analysts clearly believe Biomerica is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 18.0% of Biomerica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kyntra Bio beats Biomerica on 12 of the 15 factors compared between the two stocks.

How does Biomerica compare to Barinthus Biotherapeutics?

Biomerica (NASDAQ:BMRA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Biomerica had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Biomerica and 0 mentions for Barinthus Biotherapeutics. Biomerica's average media sentiment score of 0.67 beat Barinthus Biotherapeutics' score of 0.00 indicating that Biomerica is being referred to more favorably in the media.

Company	Overall Sentiment
Biomerica	Positive
Barinthus Biotherapeutics	Neutral

Biomerica presently has a consensus price target of $9.00, suggesting a potential upside of 334.78%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 455.56%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Barinthus Biotherapeutics' return on equity of -63.83% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Biomerica has higher revenue and earnings than Barinthus Biotherapeutics. Biomerica is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.48	-$4.97M	-$0.89	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.29	N/A

22.3% of Biomerica shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 18.0% of Biomerica shares are held by insiders. Comparatively, 10.7% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biomerica has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Biomerica on 8 of the 15 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRA vs. The Competition

Export

Metric	Biomerica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.40M	$2.94B	$6.43B	$12.05B
Dividend Yield	N/A	1.69%	2.67%	5.56%
P/E Ratio	-2.33	17.68	23.75	23.75
Price / Sales	1.48	297.12	480.27	84.51
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	1.29	3.83	10.28	6.78
Net Income	-$4.97M	$75.85M	$3.57B	$337.51M
7 Day Performance	-12.29%	-4.52%	-1.43%	-2.72%
1 Month Performance	-6.76%	-5.85%	3.27%	1.87%
1 Year Performance	-38.76%	15.31%	23.37%	26.61%

Biomerica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRA Biomerica	1.5969 of 5 stars	$2.07 -2.4%	$9.00 +334.8%	-37.3%	$6.40M	$4.33M	N/A	60	Analyst Downgrade
PLRZ Polyrizon	0.9275 of 5 stars	$14.09 -8.6%	N/A	+169.3%	$28.84M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
NEUP Neuphoria Therapeutics	2.8331 of 5 stars	$4.89 -7.7%	$21.00 +329.4%	-34.6%	$28.64M	$15.65M	N/A	N/A	Gap Up High Trading Volume
DYAI Dyadic International	1.9902 of 5 stars	$0.69 -11.1%	$3.00 +335.0%	-28.2%	$28.28M	$3.09M	N/A	7	Gap Up
KYNB Kyntra Bio	0.6875 of 5 stars	$6.84 -0.9%	N/A	N/A	$27.93M	$6.44M	0.17	570	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomerica (BMRA) Competitors

BMRA vs. PLRZ, NEUP, DYAI, KYNB, and BRNS

How does Biomerica compare to Polyrizon?

Summary

How does Biomerica compare to Neuphoria Therapeutics?

Summary

How does Biomerica compare to Dyadic International?

Summary

How does Biomerica compare to Kyntra Bio?

Summary

How does Biomerica compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomerica (BMRA) Competitors

BMRA vs. PLRZ, NEUP, DYAI, KYNB, and BRNS

How does Biomerica compare to Polyrizon?

Does the media prefer BMRA or PLRZ?

Is BMRA or PLRZ more profitable?

Which has more risk and volatility, BMRA or PLRZ?

Do institutionals & insiders believe in BMRA or PLRZ?

Which has stronger valuation & earnings, BMRA or PLRZ?

Do analysts recommend BMRA or PLRZ?

Summary

How does Biomerica compare to Neuphoria Therapeutics?

Do analysts rate NEUP or BMRA?

Does the media favor NEUP or BMRA?

Which has preferable valuation & earnings, NEUP or BMRA?

Is NEUP or BMRA more profitable?

Which has more risk and volatility, NEUP or BMRA?

Do insiders and institutionals believe in NEUP or BMRA?

Summary

How does Biomerica compare to Dyadic International?

Do analysts rate BMRA or DYAI?

Does the media prefer BMRA or DYAI?

Which has more volatility & risk, BMRA or DYAI?

Do institutionals and insiders have more ownership in BMRA or DYAI?

Is BMRA or DYAI more profitable?

Which has preferable earnings & valuation, BMRA or DYAI?

Summary

How does Biomerica compare to Kyntra Bio?

Which has more volatility and risk, KYNB or BMRA?

Does the media refer more to KYNB or BMRA?

Which has higher valuation & earnings, KYNB or BMRA?

Is KYNB or BMRA more profitable?

Do analysts recommend KYNB or BMRA?

Do institutionals & insiders believe in KYNB or BMRA?

Summary

How does Biomerica compare to Barinthus Biotherapeutics?

Does the media prefer BMRA or BRNS?

Do analysts prefer BMRA or BRNS?

Is BMRA or BRNS more profitable?

Which has better valuation and earnings, BMRA or BRNS?

Do institutionals and insiders hold more shares of BMRA or BRNS?

Which has more risk and volatility, BMRA or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools